We are scientists, engineers and biologists that want to reinvent the way we develop new drugs. Not just by drug discovery improvements, but rethinking how we use AI in the age of biological engineering to build the pharma company of the future. 

Despite trillions invested in research and drug discovery, the efficiency with which this knowledge is converted into new, high‑impact medicines remains low. Many fatal diseases continue to cause deaths every day worldwide. Traditional drug discovery is 10-15 years, $2.6B average per approved drug, 90% failure rate in clinical trials.

Most AI drug discovery companies focus on better prediction models and massive high-throughput platforms to generate more data. But without the complete biological picture, they will not generate the breakthrough treatments we need.